Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.contributor.author||van Beek, I.||en|
|dc.identifier.citation||Journal of Hepatology, 2011; 55(1):76-85||en|
|dc.description.abstract||Background & Aims: Adherence to HCV therapy impacts sustained virological response (SVR) but there are limited data on adherence, particularly among injecting drug users (IDUs). We assessed 80/80 adherence (80% of PEG-IFN doses, 80% treatment), on-treatment adherence, and treatment completion in a study of treatment of recent HCV infection (ATAHC). Methods: Participants with HCV received pegylated interferon (PEG-IFN) alfa-2a (180 μg/week, n = 74) and those with HCV/HIV received PEG-IFN alfa-2a with ribavirin (n = 35), for a planned 24 weeks. Logistic regression analyses were used to identify predictors of PEG-IFN 80/80 adherence. Results: A total of 109 out of 163 patients received treatment (HCV, n = 74; HCV/HIV, n = 35), with 75% ever reporting IDU. The proportion with 80/80 PEG-IFN adherence was 82% (n = 89). During treatment, 14% missed 1 dose (on-treatment adherence = 99%). Completion of 0–4, 5–19, 20–23, and all 24 weeks of PEG-IFN therapy occurred in 10% (n = 11), 14% (n = 15), 6% (n = 7) and 70% (n = 76) of cases, respectively. Participants with no tertiary education were less likely to have 80/80 PEG-IFN adherence (AOR 0.29, p = 0.045). IDU prior to or during treatment did not impact 80/80 PEG-IFN adherence. SVR was higher among those patients with 80/80 PEG-IFN adherence (67% vs. 35%, p = 0.007), but similar among those with and without missed doses during therapy (73% vs. 60%, p = 0.309). SVR in those patients discontinuing therapy between 0–4, 5–19, 20–23, and 24 weeks was 9%, 33%, 43%, and 76%, respectively (p <0.001). Conclusions: High adherence to treatment for recent HCV was observed, irrespective of IDU prior to, or during, therapy. Sub-optimal PEG-IFN exposure was mainly driven by early treatment discontinuation rather than missed doses during therapy.||en|
|dc.description.statementofresponsibility||Jason Grebely, Gail V. Matthews, Margaret Hellard, David Shaw, Ingrid van Beek, Kathy Petoumenos, Maryam Alavi, Barbara Yeung, Paul S. Haber, Andrew R. Lloyd, John M. Kaldor, Gregory J. Dore, For the ATAHC Study Group||en|
|dc.rights||Copyright © 2010 European Association for the Study of the Liver; Published by Elsevier Ireland Ltd.||en|
|dc.subject||Injection previous termdrug usersnext term; HIV previous terminfectionnext term; Discontinuation; Pegylated interferon; Therapy||en|
|dc.title||Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users||en|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.